Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach.

ABSTRACT:

Purpose

Telotristat etiprate, a tryptophan hydroxylase inhibitor, was previously evaluated in a Phase II randomized, placebo-controlled clinical trial in patients with carcinoid syndrome (CS) and diarrhea not adequately controlled by octreotide. The objective of the current study was to characterize the symptom experiences of patients participating in that trial.

Methods

Consenting patients participated in one-on-one, qualitative interviews focused on eliciting symptoms they had experienced in association with their CS diagnosis and recollection of symptom changes they experienced while participating in the Phase II trial.

Findings

Among the 23 patients who participated in the previous 4-week dose-escalation study, 16 were eligible for interviews and 11 participated i

SUBMITTER: Gelhorn HL 

PROVIDER: S-EPMC9047308 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature